Related Experiment Video
Updated: Jul 26, 2025
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
The Practical Role of FEF25-75 in Young Patients with Allergic Rhinitis.
Ignazio Cirillo1, Irene Schiavetti2, Fabio L M Ricciardolo3
1Navy Medical Service, La Spezia, Italy.
Allergic rhinitis patients may show early lung function decline. Impaired forced expiratory flow at 25%-75% (FEF25-75) is linked to asthma development, suggesting spirometry is vital for monitoring allergic rhinitis progression.
Area of Science:
- Respiratory Medicine
- Allergology
- Pulmonology
Background:
- Allergic rhinitis (AR) is a significant risk factor for asthma development.
- Early impairment of lung function in AR patients is a growing concern.
- Forced expiratory flow at 25%-75% of vital capacity (FEF25-75) may indicate bronchial changes in AR.
Purpose of the Study:
- To investigate the role of FEF25-75 in assessing bronchial impairment in young adults with AR.
- To determine the association between FEF25-75 and other clinical parameters in AR patients.
Main Methods:
- Cross-sectional study of 759 AR patients (mean age 29.2 years).
- Parameters assessed included medical history, BMI, lung function (FEV1, FVC, FEF25-75), bronchial hyperresponsiveness (BHR), and fractional exhaled nitric oxide (FeNO).
Main Results:
- Low FEF25-75 values were significantly associated with higher BMI, lower FEV1 and FEV1/FVC ratios, and the presence of BHR.
- Sensitization to house dust mites, longer AR duration, and higher FeNO levels were associated with BHR.
- High FeNO levels (>50 ppb) strongly correlated with BHR (OR 39).
Conclusions:
- FEF25-75 is associated with reduced lung function (FEV1, FEV1/FVC) and BHR in AR patients.
- Impaired FEF25-75 may signal early progression towards asthma.
- Spirometry, particularly FEF25-75 assessment, is recommended for long-term monitoring of AR patients.
More Related Videos
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
06:08Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
Published on: September 22, 2023
Related Concept Videos
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
01:25Pulmonary Function Tests
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...